Yu, An-LiAn-LiYuChen, Yi-ChiehYi-ChiehChenCHENG-HSUAN TSAIWu, Yuan-Kun AdenYuan-Kun AdenWuChou, Chia-HungChia-HungChouMAO-YUAN SUHsueh, Hsueh-WenHsueh-WenHsuehCHIA-TUNG SHUNJYH-MING JIMMY JUANGLee, Ming-JenMing-JenLeeHsu, Chia-HuaChia-HuaHsuPING-HUEI TSENGChao, Chi-ChaoChi-ChaoChaoYEN-HUNG LINMEI-FANG CHENGCHI-LUN KOSUNG-TSANG HSIEH2024-03-012024-03-012024-01-162047-9980https://scholars.lib.ntu.edu.tw/handle/123456789/640052Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM.en99mTc‐pyrophosphate; eplontersen; hereditary transthyretin amyloidosis; single‐photon emission computed tomography/computed tomography[SDGs]SDG3journal article10.1161/JAHA.123.030512382142772-s2.0-85182588177